Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

NCT06034860 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Termination

Conditions

Non Small Cell Lung Cancer
Hepatocellular Carcinoma
Melanoma
Renal Cell Carcinoma
Microsatellite Instability High
Mismatch Repair Deficiency
Mesothelioma
Esophageal Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Cervical Cancer

Interventions

DRUG: MT-8421
DRUG: Nivolumab

Sponsor

Molecular Templates, Inc.